TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative
French TechBio startup Cure51 has selected 10x Genomics' Visium HD technology for analyzing tumor samples from exceptional cancer survivors. The initiative aims to study over 1,000 tumor samples across 40 countries in collaboration with more than 50 medical institutions over the next 18 months. Cure51 will use Visium HD's single cell-scale resolution capabilities to build the first proprietary multi-omics database of exceptional cancer survivors, focusing on understanding survival mechanisms for new therapeutic approaches. The company recently raised €15 million in Seed funding from Sofinnova, LifeX and Hitachi Ventures.
La startup francese TechBio Cure51 ha selezionato la tecnologia Visium HD di 10x Genomics per analizzare campioni di tumori da eccezionali sopravvissuti al cancro. L'iniziativa mira a studiare oltre 1.000 campioni tumorali in 40 paesi, collaborando con più di 50 istituzioni mediche nei prossimi 18 mesi. Cure51 utilizzerà le capacità di risoluzione a scala di singole cellule di Visium HD per costruire il primo database proprietario multi-omics di eccezionali sopravvissuti al cancro, concentrandosi sulla comprensione dei meccanismi di sopravvivenza per nuovi approcci terapeutici. L'azienda ha recentemente raccolto 15 milioni di euro in finanziamenti Seed da Sofinnova, LifeX e Hitachi Ventures.
La startup francesa TechBio Cure51 ha seleccionado la tecnología Visium HD de 10x Genomics para analizar muestras de tumores de sobrevivientes excepcionales de cáncer. La iniciativa tiene como objetivo estudiar más de 1,000 muestras de tumores en 40 países, en colaboración con más de 50 instituciones médicas durante los próximos 18 meses. Cure51 utilizará las capacidades de resolución a escala de célula única de Visium HD para construir la primera base de datos multi-omics propietaria de sobrevivientes excepcionales de cáncer, centrando su atención en comprender los mecanismos de supervivencia para nuevos enfoques terapéuticos. La compañía recaudó recientemente 15 millones de euros en financiamiento Seed de Sofinnova, LifeX y Hitachi Ventures.
프랑스의 TechBio 스타트업 Cure51은 10x Genomics의 Visium HD 기술을 선택하여 뛰어난 암 생존자들의 종양 샘플을 분석합니다. 이 이니셔티브는 향후 18개월 동안 40개국에서 50개 이상의 의료 기관과 협력하여 1,000개 이상의 종양 샘플을 연구하는 것을 목표로 하고 있습니다. Cure51은 Visium HD의 단일 세포 해상도 기능을 사용하여 뛰어난 암 생존자의 첫 번째 독점 멀티 오믹스 데이터베이스를 구축하고 생존 메커니즘을 이해하여 새로운 치료 접근 방식을 개발하는 데 집중할 것입니다. 이 회사는 최근 Sofinnova, LifeX 및 Hitachi Ventures로부터 1,500만 유로의 시드 자금을 모집했습니다.
La startup française TechBio Cure51 a sélectionné la technologie Visium HD de 10x Genomics pour analyser des échantillons de tumeur provenant de survivants exceptionnels du cancer. L'initiative vise à étudier plus de 1 000 échantillons de tumeurs dans 40 pays en collaboration avec plus de 50 institutions médicales au cours des 18 prochains mois. Cure51 utilisera les capacités de résolution à l'échelle des cellules uniques de Visium HD pour construire la première base de données multi-omics propriétaire de survivants exceptionnels du cancer, en se concentrant sur la compréhension des mécanismes de survie pour de nouvelles approches thérapeutiques. L'entreprise a récemment levé 15 millions d'euros en financement Seed auprès de Sofinnova, LifeX et Hitachi Ventures.
Das französische TechBio-Startup Cure51 hat die Technologie Visium HD von 10x Genomics ausgewählt, um Tumorproben von außergewöhnlichen Krebspatienten zu analysieren. Das Ziel der Initiative ist es, über 1.000 Tumorproben aus 40 Ländern in Zusammenarbeit mit mehr als 50 medizinischen Institutionen in den nächsten 18 Monaten zu untersuchen. Cure51 wird die Auflösungsfähigkeiten von Visium HD auf Einzelzellebene nutzen, um die erste proprietäre Multi-Omics-Datenbank außergewöhnlicher Krebspatienten aufzubauen, wobei der Fokus auf dem Verständnis der Überlebensmechanismen für neue therapeutische Ansätze liegt. Das Unternehmen hat kürzlich 15 Millionen Euro an Seed-Finanzierung von Sofinnova, LifeX und Hitachi Ventures gesammelt.
- Partnership with established biotech company 10x Genomics (TXG)
- Access to advanced Visium HD technology for precise tumor analysis
- Large-scale study covering 1,000+ tumor samples across 40 countries
- Recent €15 million Seed funding secured
- None.
Insights
This partnership marks a significant development in cancer research methodology. The deployment of Visium HD technology for analyzing 1,000+ tumor samples from exceptional survivors represents an innovative approach to drug discovery. The single cell-scale resolution capability allows unprecedented detailed mapping of tumor microenvironments, potentially revealing previously undetectable survival mechanisms.
The initiative's scale and focus on exceptional survivors could accelerate the identification of novel drug targets and therapeutic pathways. Cure51's
This deal represents a strategic win for 10x Genomics, validating their Visium HD technology in a high-profile research initiative. The partnership with Cure51, backed by prominent investors like Sofinnova and Hitachi Ventures, could lead to increased adoption of 10x's technology in the growing precision medicine market. The project's ambitious scope and potential for discovering new drug targets could generate significant recurring revenue through reagent sales and potentially lead to additional partnerships in the pharmaceutical sector.
Cure51 plans to analyze more than 1,000 tumor samples from exceptional cancer survivors
Working alongside more than 50 medical institutions, Cure51 intends to collect and analyze tumor tissues from over 1,000 exceptional cancer survivors across 40 countries in the next 18 months. By using Visium HD from 10x Genomics, Cure51 aims to uncover new insights into long-term cancer survival mechanisms and build the first proprietary multi-omics database of exceptional cancer survivors.
10x Genomics' Visium HD assay, launched earlier this year, enables researchers to perform whole transcriptome spatial gene expression analysis at single cell-scale resolution. The assay will enable Cure51's scientific and biocomputational teams and partners to generate spatial molecular profiling of tumor samples at single cell-scale resolution and gain insights into the complex interactions between the tumor cells and their microenvironment. The findings will be used to better understand the cellular mechanisms behind cancer survival with the potential to uncover new approaches for precision medicine and drug target discovery.
"At Cure51, we are reverse engineering the cure to cancer. We're rounding up the most knowledgeable experts in the world and leveraging tech and data to reveal the hidden biology of miraculous survivors. Today's announcement is a huge step forward, as rolling out this type of precision tech onto cancerous tumors will open up research and drug discovery avenues that are simply unmatched today. We believe cancer can be a disease of the past, and we're devoting our lives and careers to creating the right tech to prove it," said Nicolas Wolikow and Simon Istolainen, Cure51 co-Founders, who raised
"We are thrilled Cure51 selected Visium HD for their novel work to unravel the complexities of cancer and better understand the unique biology of the outliers who defied their diagnosis," said Ben Hindson, Co-founder and Chief Scientific Officer of 10x Genomics. "Innovative research like this reinforces our belief in the power and potential of 10x technology to transform how we diagnose, treat and ultimately cure cancer."
About Cure 51
Cure51 is a French 'TechBio' company founded by Nicolas Wolikow and Simon Istolainen, alongside seasoned entrepreneurs and five world-renowned oncology centers: Gustave Roussy Institute (IGR,
Cure51's exclusive data collection system, based on partnerships, enables the creation of a unique multimodal and multiomics database of Outliers. Using its discovery platform powered by computational modeling, Cure51 aims to understand the biological mechanisms responsible for this exceptional survival by identifying and validating targets that can act on these interactions, leading to first in class treatments. This research involves the use of all relevant models (in silico, in vitro, in vivo, ex vivo) and the integration of existing literature and available databases, along with the engagement of Cure51's KOL community. Ultimately, drug design will be subject to collaboration contracts with the industry. Further information can be found at www.cure51.com
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter).
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which fall under the "safe harbor" provisions of those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s products, performance, configuration, capabilities, usage and anticipated projects utilizing 10x Genomics technologies. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. Other risks and uncertainties that could affect 10x Genomics' financial and operating results and cause actual results to differ materially from those suggested by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents 10x Genomics files with the Securities and Exchange Commission (the "SEC") from time to time. Although 10x Genomics believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance, usage and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to 10x Genomics as of the date hereof, and 10x Genomics disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics' views as of any date subsequent to the date of this press release.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/techbio-startup-cure51-selects-10x-genomics-visium-hd-for-new-drug-discovery-initiative-302292267.html
SOURCE 10x Genomics, Inc.
FAQ
What technology did Cure51 select for their cancer research initiative?
How many tumor samples will Cure51 analyze using 10x Genomics' (TXG) Visium HD?
What is the purpose of Cure51's partnership with 10x Genomics (TXG)?
How much funding did Cure51 raise before partnering with 10x Genomics (TXG)?
